{"id":"azd6244-dosing-period-3","safety":{"commonSideEffects":[{"rate":"34%","effect":"Diarrhea"},{"rate":"24%","effect":"Nausea"},{"rate":"17%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1614701","moleculeType":"Small molecule","molecularWeight":"457.69"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD6244 is a potent and selective inhibitor of MEK1 and MEK2, enzymes that are key regulators of the MAPK/ERK signaling pathway.","oneSentence":"MEK inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:57:52.207Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT05101148","phase":"PHASE1","title":"Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-07-21","conditions":"Neurofibromatosis Type 1","enrollment":24},{"nctId":"NCT02546661","phase":"PHASE1","title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2016-12-28","conditions":"Muscle Invasive Bladder Cancer","enrollment":117},{"nctId":"NCT01635023","phase":"PHASE1","title":"A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Healthy Volunteers","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZD6244"],"phase":"phase_1","status":"active","brandName":"AZD6244 Dosing Period 3","genericName":"AZD6244 Dosing Period 3","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MEK inhibitor Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}